Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company focusing on FDA-approved dermatological treatments, has announced it will release its second quarter 2024 financial results on August 12, 2024, after U.S. market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Interested parties can join the call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international). Participants can also register online to receive a dial-in number. A live audio webcast will be available on the company's website and will remain accessible for approximately 30 days after the call.
Journey Medical (Nasdaq: DERM), un'azienda farmaceutica in fase commerciale specializzata in trattamenti dermatologici approvati dalla FDA, ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 il 12 agosto 2024, dopo la chiusura del mercato statunitense. L'azienda terrà una conference call e una trasmissione audio in diretta alle 16:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale.
Le parti interessate possono partecipare alla chiamata componendo il numero 1-866-777-2509 (nazionale) o 1-412-317-5413 (internazionale). I partecipanti possono anche registrarsi online per ricevere un numero di accesso. Una trasmissione audio in diretta sarà disponibile sul sito web dell'azienda e rimarrà accessibile per circa 30 giorni dopo la chiamata.
Journey Medical (Nasdaq: DERM), una compañía farmacéutica en etapa comercial centrada en tratamientos dermatológicos aprobados por la FDA, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 12 de agosto de 2024, después del cierre del mercado estadounidense. La compañía llevará a cabo una conferencia telefónica y una transmisión web de audio a las 4:30 p.m. ET en el mismo día para discutir los resultados y proporcionar una actualización corporativa.
Las partes interesadas pueden unirse a la llamada marcando el número 1-866-777-2509 (nacional) o 1-412-317-5413 (internacional). Los participantes también pueden registrarse en línea para recibir un número de acceso. Una transmisión de audio en vivo estará disponible en el sitio web de la compañía y permanecerá accesible durante aproximadamente 30 días después de la llamada.
Journey Medical (Nasdaq: DERM)는 FDA에서 승인한 피부과 치료에 중점을 둔 상장 제약 회사로서, 2024년 2분기 재무 결과를 2024년 8월 12일 미국 시장 마감 후에 발표할 것이라고 밝혔습니다. 회사는 같은 날 오후 4시 30분 ET에 결과를 논의하고 회사 업데이트를 제공하기 위한 전화 회의 및 오디오 웹캐스트를 개최할 예정입니다.
관심 있는 분들은 1-866-777-2509 (국내) 또는 1-412-317-5413 (국제)으로 전화하여 회의에 참여할 수 있습니다. 참가자는 또한 전화 접속 번호를 받기 위해 온라인 등록을 할 수 있습니다. 실시간 오디오 웹캐스트는 회사 웹사이트에서 제공되며, 통화 후 약 30일 동안 접근 가능합니다.
Journey Medical (Nasdaq: DERM), une société pharmaceutique en phase commerciale axée sur les traitements dermatologiques approuvés par la FDA, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 12 août 2024, après la clôture du marché américain. La société tiendra une conférence téléphonique et un webinaire audio à 16h30 ET le même jour pour discuter des résultats et fournir une mise à jour de l'entreprise.
Les parties intéressées peuvent participer à l'appel en composant le 1-866-777-2509 (national) ou le 1-412-317-5413 (international). Les participants peuvent également s'inscrire en ligne pour recevoir un numéro d'appel. Un webinaire audio en direct sera disponible sur le site web de l'entreprise et restera accessible pendant environ 30 jours après l'appel.
Journey Medical (Nasdaq: DERM), ein Unternehmen in der kommerziellen Phase, das sich auf von der FDA genehmigte dermatologische Behandlungen konzentriert, gab bekannt, dass es seine finanziellen Ergebnisse für das zweite Quartal 2024 am 12. August 2024, nach dem US-Marktschluss, veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und eine Audio-Webcast veranstalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Interessierte Parteien können sich an der Konferenz beteiligen, indem sie 1-866-777-2509 (national) oder 1-412-317-5413 (international) anrufen. Teilnehmer können sich auch online registrieren, um eine Einwahlnummer zu erhalten. Ein Live-Audio-Webcast wird auf der Unternehmenswebsite verfügbar sein und bleibt etwa 30 Tage nach der Konferenz zugänglich.
- None.
- None.
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET
SCOTTSDALE, Ariz., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2024 financial results after the U.S. financial markets close on Monday, August 12, 2024. Journey Medical management will conduct a conference call and audio webcast on Monday, August 12, 2024 at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10190841/fd0fed9bae. Please note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When will Journey Medical (DERM) release its Q2 2024 financial results?
What time is Journey Medical's (DERM) Q2 2024 earnings call scheduled for?
How can investors join Journey Medical's (DERM) Q2 2024 earnings call?
Where can I find the webcast for Journey Medical's (DERM) Q2 2024 earnings call?
